Suppliers and packagers for generic pharmaceutical drug: ESOMEPRAZOLE MAGNESIUM

ESOMEPRAZOLE MAGNESIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	208333	ANDA	Ascend Laboratories, LLC	67877-478-05	500 CAPSULE, DELAYED RELEASE in 1 BOTTLE (67877-478-05)	2017-10-20
Alkem Labs Ltd	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	208333	ANDA	Ascend Laboratories, LLC	67877-478-10	1000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (67877-478-10)	2017-10-20
Alkem Labs Ltd	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	208333	ANDA	Ascend Laboratories, LLC	67877-478-30	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (67877-478-30)	2017-10-20

ESOMEPRAZOLE MAGNESIUM Suppliers: API and Finished-Dose Manufacturers, Key Supply Sources, and Procurement Risk Signals

Last updated: May 24, 2026

Esomeprazole magnesium has a mature global supply chain with multiple API sources and a wide base of contract manufacturers for tablets. Supplier selection typically hinges on (1) whether you need US DMF-listed esomeprazole magnesium (API) versus generic finished dosage manufacturing, (2) whether you need specific strengths and release profiles (immediate-release vs delayed-release pellets/tablets), and (3) whether you require FDA-compliant facilities supporting commercial ANDA manufacture.

Which companies supply esomeprazole magnesium API for generic drug manufacturing?

Featured snippet: Esomeprazole magnesium API is sourced globally by multiple established API manufacturers and specialty chemical suppliers that support generic tablet and capsule production.

Because “esomeprazole magnesium suppliers” spans API and finished dosage, procurement teams usually break sourcing into two buckets: API (active) and drug product (manufacturing and packaging).

API supplier categories for esomeprazole magnesium

1. Large-scale chemical API producers
   These firms typically offer DMF-backed API or support regulatory documentation packages used by ANDA applicants.
2. Specialty generic API suppliers
   These vendors focus on key proton pump inhibitor (PPI) APIs with recurring supply to generic formulators.
3. Contract manufacturing groups that bundle API-to-finished services
   Some CDMOs maintain internal API capability or manage qualified external API supply plus drug product manufacturing.

What to confirm in supplier due diligence

• DMF status and letter of access availability for the API if the target filing is US-based.
• Compliance history tied to cGMP and inspection outcomes for the specific site that will supply your batch.
• Salt-grade specifications (quality and polymorph control) because “esomeprazole magnesium” is a salt form with defined specifications in commercial use.
• Impurity profile control aligned to pharmacopeial and regulatory thresholds used in ANDA dossiers.

Who are the major esomeprazole magnesium drug product (tablet/capsule) manufacturers?

Featured snippet: Finished-dose esomeprazole magnesium is manufactured by a broad set of generic and CDMO players producing delayed-release tablets or capsules depending on the product.

Typical finished-dose forms sourced for esomeprazole magnesium

• Delayed-release tablets (common for esomeprazole magnesium in the market)
• Delayed-release capsules (less common, but used for certain markets/product lines)

Procurement implications

• Tablet manufacturing requires validated processes for enteric/delayed-release coatings.
• Supplier capability matters for gastric-resistant coating integrity, dose uniformity, and dissolution performance.

Does esomeprazole magnesium API supplier status depend on DMF/ANDA pathway?

Featured snippet: For US generics, the highest-friction supplier step is regulatory documentation, especially DMF content and access arrangements used by ANDA applicants.

Common regulatory supply models

• ANDA applicant uses a DMF-listed API supplier
  Applicant requests a Letter of Access to reference DMF data.
• Applicant builds its own DMF route
  Supplier provides commercial API, while the applicant files its own documentation package.
• Filing support by CDMO
  CDMO supplies either API or drug product with regulatory packages supporting the dossier.

Risk drivers

• A supplier that is “commercially available” may still be unsuitable for US filings if DMF access is limited, or if the site has a compliance history incompatible with your quality requirements.

What are common contract manufacturing routes for esomeprazole magnesium?

Featured snippet: Most contract routes focus on delayed-release solid oral dosage manufacturing with tight dissolution and coating controls.

Contract manufacturing scope most vendors offer

• API procurement management or qualified sourcing
• Solid oral dosage manufacturing (granulation, tableting, coating)
• Packaging and labeling operations (unit-dose packaging, bottle lines, blister if required)

Key technical gates buyers set

• Coating validation for delayed-release behavior
• Dissolution method alignment with reference product specs
• Process capability for tablet hardness, friability, and uniformity

Where are esomeprazole magnesium suppliers located geographically?

Featured snippet: Supply is widely distributed across North America, Europe, and Asia with the heaviest concentration of API capacity in Asia and drug product manufacturing distributed across multiple regions.

Common geographic patterns

• API manufacturing concentration: Asia-based plants are frequent sources of bulk PPIs.
• Drug product manufacturing: Multi-region CDMOs and generic manufacturers produce delayed-release tablets for export and local market needs.

Procurement risk signals by region

• Long lead times and port/logistics constraints can affect API availability.
• Site-specific cGMP and inspection outcomes drive selection more than national-level reputation.

What supply-chain constraints affect availability of esomeprazole magnesium?

Featured snippet: Supply constraints usually track generic API capacity, coating/input material sourcing, and regulatory/compliance events at specific manufacturing sites rather than the drug’s overall demand alone.

Demand and capacity pressures

• As a long-established generic, volumes are stable but capacity shifts happen when suppliers repurpose lines or face compliance remediation.

Regulatory or compliance events that can disrupt supply

• FDA/EMA inspection findings at API or drug product sites
• Recalls or quality notifications related to impurities, dissolution failure, or stability excursions

How do esomeprazole magnesium suppliers compare on regulatory and quality readiness?

Featured snippet: Buyers typically screen suppliers on (1) regulatory documentation readiness (DMF/CoA history), (2) cGMP inspection track record, and (3) ability to sustain consistent dissolution and coating performance.

Comparative evaluation matrix (procurement-ready)

Supplier category	Strengths	Usual gaps to audit
DMF-backed API supplier	Easier US dossier path via Letter of Access	Access limitations, documentation version control
CDMO with integrated process	Faster commercialization timelines	Dependency on a single coating/dissolution method and shared dependencies
Commodity API supplier	Price competitiveness	Higher diligence burden for impurities, specs, and inspection history
Regional manufacturer	Shorter logistics and localized QA	Smaller batches or fewer global packaging capabilities

What supplier choices are safest for commercial continuity?

Featured snippet: The safest procurement strategy is dual sourcing with at least one qualified alternate site for both API and drug product steps.

Buyer best practices

• Qualify at least two independent API sources and validate interchangeability at the batch level.
• Qualify at least two packaging configurations if label/bottle/blister formats differ across markets.
• Put quality agreements in place that define: impurity thresholds, CoA requirements, change control triggers, and notification timelines.

Key Takeaways

• Esomeprazole magnesium supply is broad, but supplier suitability depends on regulatory readiness (DMF/Letter of Access for API), cGMP compliance at the specific site, and the ability to produce delayed-release solid oral dosage with validated dissolution and coating performance.
• Procurement risk clusters around site-specific compliance events, quality deviations, and documentation access constraints.
• Commercial continuity improves with dual sourcing for both API and finished-dose manufacturing, supported by quality agreements and batch-level interchangeability validation.

FAQs

Which API quality documents should I require from esomeprazole magnesium suppliers?

Require an up-to-date CoA with batch-specific impurity profile, a specification sheet, and change-control history tied to validated specs used in your regulatory pathway.

Can a CDMO manufacture esomeprazole magnesium delayed-release tablets using any API supplier?

Only if API is qualified for your specific process and dissolution targets, with documented interchangeability and regulatory alignment for your dossier.

What are the biggest drivers of delayed-release failure risk in esomeprazole magnesium tablets?

Coating process drift, enteric polymer variability, inadequate curing parameters, and dissolution method misalignment versus reference product targets.

Do esomeprazole magnesium suppliers offer regulatory support for ANDA filings?

Some suppliers provide DMF-backed documentation and Letter of Access support; others support through CoA/spec data and technical transfer. The deciding factor is whether your dossier can reference their regulatory package.

Is there substitution risk between esomeprazole magnesium and other esomeprazole salts?

Salt forms differ in specifications and process behavior. Interchangeability must be demonstrated at the drug product level through dissolution and quality comparability studies.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-24).
2. FDA. Drug Master Files (DMF) program information. (Accessed 2026-05-24).
3. EMA. Guideline: GMP requirements for manufacturing sites. (Accessed 2026-05-24).